Hutch News

Hutch News

Stories tagged 'Lymphoma'

Pacific NW Magazine profiles Fred Hutch’s pursuit of cancer cures

Seattle Times’ Sunday feature looks at the melding of expertise, drive and technology making new cures possible

May 17, 2018 | By Fred Hutch staff

Cover story of Seattle Times’ Pacific NW Magazine explores why Fred Hutchinson Cancer Research Center is closing in on cancer cures.

View story >


Mariners honor cancer survivor Colin Craig

Seattle native works to support lifesaving research — like the immunotherapy that put his cancer in remission

May 3, 2018 | By Sabrina Richards / Fred Hutch News Service

Throughout the 2018 Major League Baseball season, Fred Hutch and the Seattle Mariners are recognizing “Hutch Heroes,” including lymphoma survivor Colin Craig, who works to support our lifesaving research.

View story >


Health disparities may affect end-of-life experiences of minority blood cancer patients

A new study finds ethnic and racial minorities with leukemia or lymphoma are more likely to die in hospital, receive aggressive care in last weeks of life than white patients

Dec. 11, 2017 | By Rachel Tompa / Fred Hutch News Service

A new study of nearly 9,500 blood cancer patients revealed that racial and ethnic minority patients have a different experience at the end of their lives than do their white counterparts.

View story >


One family, two sides of cancer

Basic scientist Dr. Wenying Shou’s parents were both treated for — and cured of — their cancers. The similarities end there.

Oct. 6, 2017 | By Rachel Tompa / Fred Hutch News Service

Both of Dr. Wenying Shou's parents were diagnosed with - and cured of - cancer. The similarities end there.

View story >


Mourning the loss of Dr. Oliver 'Ollie' Press

Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies

Oct. 2, 2017 | by Susan Keown / Fred Hutch News Service

Dr. Oliver Press died of complications from glioma, a brain cancer. Press was a physician-scientist who made foundational contributions to the development of targeted therapies for blood cancers.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.